ORIC Pharmaceuticals Inc (NAS:ORIC)
$ 9.01 0.06 (0.67%) Market Cap: 607.48 Mil Enterprise Value: 288.08 Mil PE Ratio: 0 PB Ratio: 1.83 GF Score: 40/100

Oric Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 07:15PM GMT
Release Date Price: $5.78 (+2.85%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Thanks, everyone. So welcome to the final session of the Tuesday morning of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the Senior Biotech Analyst here at JPMorgan. I'm joined by Malcolm Kuno and Priyanka Grover from the team.

Our next presenting company is ORIC. And presenting on behalf of the company, we have CEO, Jacob Chacko.

Jacob M. Chacko
ORIC Pharmaceuticals, Inc. - President, CEO & Director

Thank you, Anupam. It's exciting to be in person. It's exciting to get to see folks in real life and get a chance to talk to you about ORIC Pharmaceuticals, which is our company that's developing a pipeline of drugs targeted at cancer resistance. We're quite excited about the way we've built the company, the pipeline that we've built, and I'll get a little bit of time to share that with you today. Of course, I will be making forward-looking statements during the presentation today.

So before I get into the specifics of the pipeline

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot